Unicycive Therapeutics Stock (NASDAQ: UNCY)

Unicycive Therapeutics Stock (NASDAQ:UNCY), Trade Ideas

Unicycive Therapeutics

Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

AFRM

AUUD

BTTX

CCTG

FUTU

FWBI

GIII

HEAR

HGAS

HOOD

IMRX

KPLT

MDGL

MOMO

NOVA

PANL

PATH

PERF

PIXY

PRST

PUYI

RAYA

RCMT

RGLS

RMBL

SPRB

SPRO

TCON

UNCY

WIMI

WOOF

Shares of  Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates.

Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

AGFY

ARAV

BABA

BETS

BILI

BREA

CLEU

CSIQ

DADA

ENSC

ESGL

ETAO

EVAX

FAZE

GPAK

GYRE

IBRX

LIFW

LOGI

MARK

MESO

NUTX

NVVE

PLUG

REVB

RVSN

SAVE

SGMT

SLDP

SRTS

VTAK

Shares of 3M Company (NYSE: MMM) fell sharply during Tuesday’s session after the company reported better-than-expected fourth-quarter EPS, but issued FY24 EPS guidance below estimates.

Why 3M Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Pre-Market Outlook

ACRS

ASTL

CELU

CHRS

CISS

GBNH

HNRA

HUBC

Airspan Networks Holdings Inc. Common Stock

MIMO

Nuveen Insured California Premium Fund Ii

PRCH

RILY

TCBP

WISA

Shares of  Coherus BioSciences, Inc. (NASDAQ: CHRS) shares rose sharply in today’s pre-market trading after the company announced an agreement to divest ophthalmology franchise to Sandoz in $170 million upfront all cash deal.

Why Coherus BioSciences Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket

Unicycive Therapeutics, Inc. - Common Stock

Unicycive Therapeutics Inc

<p>Truist Securities  analyst Youssef Squali   maintains Snap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) with a Hold and raises the price target from $12 to $16.</p>


Price Target

Analyst Ratings

SNAP

Truist Securities Maintains Hold on Snap, Raises Price Target to $16

<p>RBC Capital  analyst Brian Abrahams   maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Sector Perform and lowers the price target from $26 to $15.</p>


SAGE

RBC Capital Maintains Sector Perform on Sage Therapeutics, Lowers Price Target to $15

Chevron CEO Says Co Estimates Arbitration Will Conclude In Q4, Consistent With Exxon's Timeline

<p>Truist Securities  analyst Joon Lee   maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Hold and lowers the price target from $22 to $18.</p>


Truist Securities Maintains Hold on Sage Therapeutics, Lowers Price Target to $18

Chevron CEO Says Co Has Not Received Timing Schedule From Tribunal Over Arbitration Process

GOOG

GOOGL

Google Invests $3B In Data Center Campuses In Virginia, Indiana

<p>RBC Capital  analyst Craig Wong-Pan   maintains ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) with a Sector Perform and raises the price target from $187 to $200.</p>


RBC Capital Maintains Sector Perform on ResMed, Raises Price Target to $200

<p>Truist Securities  analyst Jamie Cook   maintains Oshkosh (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSK#NYSE">OSK</a>) with a Hold and raises the price target from $121 to $132.</p>


Truist Securities Maintains Hold on Oshkosh, Raises Price Target to $132

WIIM

SNOW

Snowflake shares are trading higher after Microsoft reported strong growth in Azure.

MongoDB shares are trading higher after Microsoft reported strong growth in Azure.

<p>Truist Securities  analyst Scot Ciccarelli   maintains O'Reilly Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>) with a Buy and lowers the price target from $1234 to $1212.</p>


ORLY

Truist Securities Maintains Buy on O'Reilly Automotive, Lowers Price Target to $1212

Chevron CEO Says Not Planning To Make New Investments In California

<p>Truist Securities  analyst Robyn Karnauskas   maintains Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) with a Buy and raises the price target from $142 to $143.</p>


Truist Securities Maintains Buy on Merck & Co, Raises Price Target to $143

<p>RBC Capital  analyst Ken Herbert   maintains Northrop Grumman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>) with a Sector Perform and raises the price target from $450 to $475.</p>


RBC Capital Maintains Sector Perform on Northrop Grumman, Raises Price Target to $475

<p>Truist Securities  analyst Neal Dingmann   maintains Matador Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTDR#NYSE">MTDR</a>) with a Buy and raises the price target from $85 to $87.</p>


MTDR

Truist Securities Maintains Buy on Matador Resources, Raises Price Target to $87

Macro Economic Events

Politics

Economics

General

President Biden, In Interview With Howard Stern Said, if I Am Elected Again, We Will Make Roe V. Wade The Law Of The Land Again; I Will Debate Trump, I Don't Know When

<p>Truist Securities  analyst Michael Swartz   maintains MarineMax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HZO#NYSE">HZO</a>) with a Buy and lowers the price target from $40 to $35.</p>


Truist Securities Maintains Buy on MarineMax, Lowers Price Target to $35

Applovin shares are trading higher. The stock may be up following strong earnings from Snap.

<p>Truist Securities  analyst Brandon King   maintains Live Oak Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOB#NYSE">LOB</a>) with a Buy and lowers the price target from $47 to $38.</p>


Truist Securities Maintains Buy on Live Oak Bancshares, Lowers Price Target to $38

<p>Truist Securities  analyst Ryan MacDonald   maintains Laboratory Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Buy and lowers the price target from $270 to $255.</p>


Laboratory Corporation Of America Holdings

Truist Securities Maintains Buy on Laboratory Corp, Lowers Price Target to $255

In a report released today, Robert LeBoyer from Noble Financial maintained a Buy rating on Unicycive Therapeutics (UNCY – Research Report), with a ...

Noble Financial Keeps Their Buy Rating on Unicycive Therapeutics (UNCY)

H.C. Wainwright analyst Ed Arce has maintained their bullish stance on UNCY stock, giving a Buy rating on March 11. Ed Arce has given his Buy ratin...

Buy Rating on Unicycive Therapeutics Amidst Promising UNI-494 Drug Candidate Prospects

Unicycive rises 4% on $50M private placement

The 25 rating InvestorsObserver gives to Unicycive Therapeutics Inc (UNCY)  stock puts it near the top of the Healthcare sector.In addition to scoring higher than 75 percent of stocks in the Healthcare sector, UNCYâ€&#x2122;s 25 overall rating means the stock scores better than 25 of all stocks. UNCY has an Overall Score of 25. Fin

Will Unicycive Therapeutics Inc (UNCY) Outperform the Rest of the Stocks in the Healthcare Sector?

Unicycive Therapeutics Inc (UNCY) is near the top in its industry group according to InvestorsObserver. UNCY gets an overall rating of 63. That means it scores higher than 63 percent of stocks. Unicycive Therapeutics Inc gets a 74 rank in the Biotechnology industry. Biotechnology is number 19 out of 148 industries. UNCY ha

Unicycive Therapeutics Inc (UNCY) has fallen 0.00% in a Week, Should You Accumulate?

Unicycive Therapeutics GAAP EPS of -$1.28, revenue of $0.7M

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Unicycive Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/uncy-stock-quote/"><strong>UNCY</strong></a></span>) just reported results for the fourth quarter of 2023.</p><ul><li>Unicycive Therapeutics reported earnings per share of -35 cents. This was below the analyst estimate for EPS of -17 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/03/uncy-stock-earnings-unicycive-therapeutics-for-q4-of-2023/">UNCY Stock Earnings: Unicycive Therapeutics Misses EPS for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

UNCY Stock Earnings: Unicycive Therapeutics Misses EPS for Q4 2023

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Unicycive Therapeutics (UNCY – Research Report), with a price t...

Buy Rating Affirmed for Unicycive Therapeutics Amidst Positive Milestones and Solid Financial Footing

Unicycive Therapeutics (UNCY) has received a new Buy rating, initiated by Piper Sandler analyst, Yasmeen Rahimi. Yasmeen Rahimi's rating is based o...

Unicycive Therapeutics: A Strong Buy on OLC's Potential to Revolutionize Hyperphosphatemia Treatment in CKD

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Unicycive Therapeutics (UNCY – Research Report). The associated price tar...

Buy Rating Affirmed for Unicycive Therapeutics on Strong Trial Progress and Financial Positioning

Health Care

Press Releases

Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting

Opinion

Thinking about buying stock in Summit Materials, Informatica, Unicycive Therapeutics, Tarsus Pharmaceuticals, or Zion Oil and Gas?

Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant Patients

Thinking about buying stock in Beyondspring, LAVA Therapeutics, Unicycive Therapeutics, Guardforce AI, or Infobird?

Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)

Unicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference

Financing

Unicycive Announces $50 Million Private Placement

Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress

Earnings

Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update

Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference